2022 World Conference on Lung Cancer (ePosters)-EP08.01-054. ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer

EP08.01-054. ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The objective of this study was to evaluate the effectiveness and safety of combining immune checkpoint inhibitors (ICIs) with single-agent chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) in two or more lines of therapy. The study collected clinical data from 30 patients with advanced NSCLC who received this treatment regimen. The short-term efficacy, progression-free survival (PFS), extracellular vesicle (EV) markers for response prediction, and adverse events were assessed.<br /><br />The results showed that out of the 30 patients, there were no complete responses, 5 patients had partial responses, 18 patients had stable disease, and 7 patients had disease progression. The objective response rate (ORR) was 16.7%, the disease control rate (DCR) was 76.7%, and the median PFS was 3.2 months.<br /><br />Univariate analysis showed that there were no statistically significant differences in PFS based on gender, age, smoking status, treatment lines, prior immunotherapy, or prior antivascular therapy. However, EV membrane proteins including C-MET, EGFR, and VEGFR2 were found to be negatively correlated with the efficacy of ICIs and chemotherapy. High expression of these proteins was observed in non-responders and low expression in responders. These proteins could serve as diagnostic markers for disease progression.<br /><br />The study concluded that the combination of ICIs and single-agent chemotherapy was both safe and effective with tolerable adverse events. EV markers could be used as guidance for medication and monitoring therapeutic efficacy. The results suggest that this treatment regimen could be a viable option for patients with advanced NSCLC who have undergone previous lines of therapy.

Asset Subtitle

Yutao Liu

Meta Tag

Speaker Yutao Liu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

immune checkpoint inhibitors

chemotherapy

non-small cell lung cancer

advanced NSCLC

treatment effectiveness

treatment safety

progression-free survival

extracellular vesicle markers

adverse events

response prediction